Sight Sciences (NASDAQ:SGHT) CFO James Rodberg Sells 6,902 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CFO James Rodberg sold 6,902 shares of Sight Sciences stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $5.36, for a total value of $36,994.72. Following the transaction, the chief financial officer directly owned 224,037 shares of the company’s stock, valued at $1,200,838.32. The trade was a 2.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Sight Sciences Trading Down 0.4%

Shares of SGHT opened at $5.43 on Tuesday. The business’s 50-day moving average price is $4.95 and its 200-day moving average price is $5.31. Sight Sciences, Inc. has a twelve month low of $3.11 and a twelve month high of $9.24. The stock has a market cap of $295.23 million, a PE ratio of -7.65 and a beta of 2.38. The company has a quick ratio of 5.48, a current ratio of 5.86 and a debt-to-equity ratio of 0.68.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.05). The firm had revenue of $19.70 million during the quarter, compared to the consensus estimate of $18.46 million. Sight Sciences had a negative net margin of 46.83% and a negative return on equity of 52.34%. On average, equities analysts forecast that Sight Sciences, Inc. will post -0.6 EPS for the current fiscal year.

Key Sight Sciences News

Here are the key news stories impacting Sight Sciences this week:

• Negative Sentiment: CEO Paul Badawi sold 28,684 shares, trimming his stake by about 0.47%, in the largest disclosed insider transaction. Sight Sciences (NASDAQ:SGHT) CEO Paul Badawi Sells 28,684 Shares of Stock
• Negative Sentiment: CFO James Rodberg sold 6,902 shares, reducing his ownership by nearly 3%, adding to the selling pressure from senior leadership. Sight Sciences (NASDAQ:SGHT) CFO Sells 6,902 Shares
• Negative Sentiment: CTO David Badawi sold 7,418 shares, while insider Jeremy B. Hayden sold 12,733 shares, reinforcing the pattern of insider reductions. Insider Selling: Sight Sciences (NASDAQ:SGHT) CTO Sells $40,873.18 in Stock Sight Sciences (NASDAQ:SGHT) Insider Sells 12,733 Shares of Stock
• Negative Sentiment: EVP Brenton Taylor also sold shares, continuing the broad pattern of insider selling across multiple executives. Sight Sciences (NASDAQ:SGHT) EVP Sells $15,333.18 in Stock

Institutional Trading of Sight Sciences

Several institutional investors have recently added to or reduced their stakes in the business. Integral Health Asset Management LLC purchased a new position in Sight Sciences in the 4th quarter worth approximately $3,370,000. Invesco Ltd. purchased a new stake in shares of Sight Sciences during the fourth quarter valued at approximately $2,791,000. Walleye Capital LLC purchased a new stake in shares of Sight Sciences during the fourth quarter valued at approximately $2,332,000. Informed Momentum Co LLC bought a new position in shares of Sight Sciences in the fourth quarter worth approximately $1,299,000. Finally, Americana Partners LLC grew its holdings in shares of Sight Sciences by 12.1% in the fourth quarter. Americana Partners LLC now owns 1,378,980 shares of the company’s stock worth $10,935,000 after purchasing an additional 149,161 shares during the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

SGHT has been the subject of a number of research reports. Weiss Ratings cut shares of Sight Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. Citigroup raised their price target on Sight Sciences from $4.35 to $5.15 and gave the company a “neutral” rating in a research report on Thursday, May 28th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Sight Sciences presently has a consensus rating of “Hold” and an average price target of $8.14.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.